Looks like events are settling down in the Middle East and while there are still risks, it looks like everyone is taking the offramps (for now). This should decrease the price of oil and increase the risk tolerance of the market. Of course, the sector did not do great when it appeared to settle down […]
June 18th Biotech Update
I feel worried saying this but the sector is doing well at least when one looks at the chart. This certainly does not mean that the headwinds and concerns are suddenly going away but bull markets are built on climbing a wall of worries and there are a lot of worries that could be climbed […]
June 16 Biotech Update
Despite all of the news in the market recently, we actually seem to be in a good place (at least as I look at the chart). If you take a step back, we are around 20% higher since the panic lows and there can be what looks like trend higher. There are higher highs and […]
Conavi Is Revolutionizing Coronary Interventions
I’ve primarily been focused on biotech stocks and have generally avoided medical device investments. But a month ago, a broker I’ve worked with for years called me about a new opportunity. He knows I’m selective, but he was excited about the company and wanted my take on their public financing round. When he mentioned it […]
Mailing List
Introduction
Overview
Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.
The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.
Subscribe to Chimera Research Group and proceed with confidence.
